MARKET

NUVB-WS

NUVB-WS

Nuvation Bio Inc
NYSE
0.1550
+0.0450
+40.91%
Opening 11:41 12/13 EST
OPEN
0.1250
PREV CLOSE
0.1100
HIGH
0.1550
LOW
0.1250
VOLUME
2.08K
TURNOVER
--
52 WEEK HIGH
0.4450
52 WEEK LOW
0.0350
MARKET CAP
--
P/E (TTM)
-0.0714
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NUVB WS last week (1202-1206)?
Weekly Report · 4d ago
Weekly Report: what happened at NUVB WS last week (1125-1129)?
Weekly Report · 12/02 09:19
Weekly Report: what happened at NUVB WS last week (1118-1122)?
Weekly Report · 11/25 09:18
Weekly Report: what happened at NUVB WS last week (1111-1115)?
Weekly Report · 11/18 09:17
Weekly Report: what happened at NUVB WS last week (1104-1108)?
Weekly Report · 11/11 09:19
Weekly Report: what happened at NUVB WS last week (1028-1101)?
Weekly Report · 11/04 09:19
Weekly Report: what happened at NUVB WS last week (1021-1025)?
Weekly Report · 10/28 09:18
Weekly Report: what happened at NUVB WS last week (1014-1018)?
Weekly Report · 10/21 09:18
More
About NUVB-WS
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Webull offers Nuvation Bio Inc stock information, including NYSE: NUVB WS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVB WS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUVB-WS stock methods without spending real money on the virtual paper trading platform.